Interview with Emily Cheah, General Manager, BRASS
Biomedical Research and Support Services Pte Ltd. is an NUS University spin-off that has been around for more than 14 years; last year the company name was changed to BRASS.…
Address: 33 Ubi Avenue 3,
#06-13/14 Vertex,
Singapore 408868.
33 Ubi Avenue 3, #06-13/14 Vertex, Singapore 408868.
33 Ubi Avenue 3, #06-13/14 Vertex, Singapore 408868.
33 Ubi Avenue 3, #06-13/14 Vertex,,Singapore
Tel: +65 6742 6007
Web: http://www.brass-asiapacific.com/c/
BRASS™ was conceived in the National University of Singapore (NUS) on May 1996 with the primary aim of supporting medical device development from concept into reality.
The brainchild of Assoc. Prof. Eugene Khor, BRASS™ is the answer to the biomedical industry’s need for vital infrastructure in support of the medical devices industry. BRASS™ was registered in December 1997 (hence “SINCE 1997”) and in April 1, 1999, the NUS incubation component of BRASS was granted permission to spin-off as a separate entity.
BRASS™ was awarded sole distributorship for the Charles River Endosafe brand of LAL Bacterial Endotoxin Test reagents in Singapore, Indonesia and Malaysia, an achievement that still remains to this day. With its growing success, BRASS™ was able to secure a partnership with the North American Science Associates, Inc. (NAMSA), the world leader in medical device safety evaluation, in July 2002. With this strategic alliance, BRASS™ is able to provide the full panel of GLP ISO 10993 biocompatibility testing, functional and performance studies, and material characterization to the medical device industry as well as gained the rights to distribute the full series of NAMSA Sterilization Assurance Products in several territories in the Asia Pacific region. In 2011, BRASS™ successfully attained representation for Charles River Biopharmaceutical Services in Singapore, Malaysia, Indonesia and Vietnam.
Thirteen years since its humble beginnings, BRASS™ has grown from strength to strength, and counts as its clients various multinational industry leaders, innovative start-ups and research institutes from the pharmaceutical and medical device industry in South East Asia.
Quality Product Provider: broad range of high quality and reliable media, packaging and sterilization assurance products.
Medical Device Expertise
Specialist in Microbiological Testing
Strategic and customized solutions for product development, regulatory compliance and quality assurance throughout the entire life-cycle of the medical device.
Biomedical Research and Support Services Pte Ltd. is an NUS University spin-off that has been around for more than 14 years; last year the company name was changed to BRASS.…
Why did you decide to start your own company? I started my career as a scientist with a real passion for molecular biology, and moved into pharmaceutical R&D working for…
What prompted you to found TriReme six years ago? I set up companies, so TriReme was not the first. The idea behind TriReme was to provide solutions for complex cases,…
Singapore wants to be seen as a springboard for Asia, but that is a position that other countries in Asia would also like to hold. In general, executives prefer to…
Since the last time we had the pleasure of meeting you, 4 years ago, what have been the main developments and changes in the Singaporean pharmaceutical industry? One of the…
Central Asia, what is Central Asia in the BD perspective? For us, Central Asia includes all the countries in Asia, except Greater China, India and Japan. What have been the…
The company’s current corporate strategy includes a major focus on the Emerging Markets and Asia Pacific (EMAP) region. Concretely, what are the expectations and the main objectives for the Asia…
Please give us an overview of HOYA Surgical Optics and its operations. HOYA Surgical Optics is a global manufacturer of intraocular lenses (IOLs) — the artificial lens that is put…
There has been much hype about emerging markets, especially those in Asia. How important are these markets for GE and what are your respective goals for the next three years?…
As a pioneering member of Arcasia, before it merged with JTC International and became what is Ascendas today, you know the history of the company very intimately. What are the…
In Q3 2012, MSD reported worldwide sales of $11.5 billion. What was the contribution that emerging markets had? From an MSD perspective, emerging markets refer to every market outside North…
Pfizer completed the acquisition of Wyeth three years ago. How did the merge impact the Singaporean operations? As the result of the merge, Pfizer in Singapore has been able to…
Prior to joining AMRI you worked in diverse companies in Japan, like Dishman, Pfizer and Bayer. What attracted you to this company? The main reason is that Singapore has growing…
See our Cookie Privacy Policy Here
